| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H30O2 |
| Molecular Weight | 302.451 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]2(C)[C@H]1O
InChI
InChIKey=FCKLFGKATYPJPG-SSTBVEFVSA-N
InChI=1S/C20H30O2/c1-3-12-11-18-17-6-4-13-10-14(21)5-7-15(13)16(17)8-9-20(18,2)19(12)22/h10,12,15-19,22H,3-9,11H2,1-2H3/t12-,15-,16+,17+,18-,19-,20-/m0/s1
| Molecular Formula | C20H30O2 |
| Molecular Weight | 302.451 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Oxendolone (brand name Prostetin; former name TSAA-291 is a steroidal antiandrogen and progestin of the 19-nortestosterone group that has been marketed in Japan by Takeda for the treatment of benign prostatic hyperplasia (BPH) since 1981. It is androgen receptor antagonist and it binds to progesterone receptor. It also acts as a weak but clinically relevant inhibitor of 5α-reductase. Oxendolone is approved for the treatment of BPH in Japan.
